Literature DB >> 8780165

Inhibition of squamous cell carcinoma angiogenesis by direct interaction of retinoic acid with endothelial cells.

M W Lingen1, P J Polverini, N P Bouck.   

Abstract

Retinoic acid (RA) is a multifunctional drug that is particularly effective at preventing the development of multiple primary oral squamous cell carcinomas. A portion of this activity is due to the inhibition of tumor angiogenesis. It has been thought that RA influences tumor angiogenesis only via its interactions with the tumor cells themselves. Here, we test the hypothesis that the drug can also block neovascularization by directly inhibiting the angiogenic activity of normal endothelial cells. Clinically achievable doses of RA rapidly caused large- and small-vessel endothelial cells to become refractory to stimulation of migration either by tumor-conditioned media or purified angiogenic factors (a-fibroblast growth factor (aFGF), bFGF, vascular endothelial GF, platelet-derived GF, TGF beta-1, and IL-8). However, RA had little effect on their proliferation. Inhibition of migration was complete within 3 hours and was reversed 36 hours after drug removal. The migration of human oral keratinocytes was not sensitive to RA, whereas the migration of fibroblasts and vascular smooth muscle cells was inhibited. To determine if systemic RA affected neovascularization, rats were given 1 mg/kg/day of all-trans RA and their angiogenic potential was tested by implanting pellets of tumor-conditioned media into their avascular corneas. This treatment rendered the rats unable to mount a neovascular response in their corneas. These data demonstrate that RA directly affects endothelial cells, rapidly and reversibly inhibiting their ability to migrate toward a variety of stimuli in vitro and halting the formation of new vessels in vivo. These direct effects on vascular cells seem likely to contribute to the success of RA as a chemopreventive agent for oral squamous cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8780165

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  10 in total

1.  A role for all-trans-retinoic acid in the early steps of lymphatic vasculature development.

Authors:  Daniela Marino; Vasilios Dabouras; André W Brändli; Michael Detmar
Journal:  J Vasc Res       Date:  2010-11-23       Impact factor: 1.934

2.  A cause of unbearably painful breast, diffuse dermal angiomatosis.

Authors:  Barbara J Adams; Stephanie Goldberg; H Davis Massey; Kazuaki Takabe
Journal:  Gland Surg       Date:  2012-08-01

Review 3.  The rationale and future potential of angiogenesis inhibitors in neoplasia.

Authors:  G Gasparini
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

4.  Neuropilin-1 participates in wound angiogenesis.

Authors:  Annette M Matthies; Quentin E H Low; Mark W Lingen; Luisa A DiPietro
Journal:  Am J Pathol       Date:  2002-01       Impact factor: 4.307

5.  Expression of human papillomavirus type 16 E7 is sufficient to significantly increase expression of angiogenic factors but is not sufficient to induce endothelial cell migration.

Authors:  Joanna Walker; Lucy Clare Smiley; David Ingram; Ann Roman
Journal:  Virology       Date:  2010-12-14       Impact factor: 3.616

6.  Retinoic acid induces cells cultured from oral squamous cell carcinomas to become anti-angiogenic.

Authors:  M W Lingen; P J Polverini; N P Bouck
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

7.  Tumor angiogenesis as a target for dietary cancer prevention.

Authors:  William W Li; Vincent W Li; Michelle Hutnik; Albert S Chiou
Journal:  J Oncol       Date:  2011-09-29       Impact factor: 4.375

8.  A potential use of a synthetic retinoid TAC-101 as an orally active agent that blocks angiogenesis in liver metastases of human stomach cancer cells.

Authors:  T Oikawa; K Murakami; M Sano; J Shibata; K Wierzba; Y Yamada
Journal:  Jpn J Cancer Res       Date:  2001-11

Review 9.  Translational Research in Retinopathy of Prematurity: From Bedside to Bench and Back Again.

Authors:  Mitsuru Arima; Yuya Fujii; Koh-Hei Sonoda
Journal:  J Clin Med       Date:  2021-01-18       Impact factor: 4.241

10.  Molecular targets and signaling pathways regulated by interleukin (IL)-24 in mediating its antitumor activities.

Authors:  Janani Panneerselvam; Anupama Munshi; Rajagopal Ramesh
Journal:  J Mol Signal       Date:  2013-12-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.